Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study

Translational Oncology

Volumn 6, Issue 6, 2013, Pages 660-669

  Ali, Meser M ^a   Kumar, Sanath ^a   Shankar, Adarsh ^a   Varma, Nadimpalli R S ^a   Iskander, A S M ^a   Janic, Branislava ^a   Chwang, Wilson B ^a   Jain, Rajan ^a   Babajeni Feremi, Abbas ^b   Borin, Thaiz F ^a   Bagher Ebadian, Hassan ^a   Brown, Stephen L ^a   Ewing, James R ^a   Arbab, Ali S ^a,c  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891685345     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13559     Document Type: Article

References (47)

1. Los M, Roodhart JM, and Voest EE (2007). Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12, 443-450.
2. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, et al. (2008). Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70, 779-787.
3. Norden AD, Drappatz J, and Wen PY (2008). Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 7, 1152-1160.
4. Dietrich J, Norden AD, and Wen PY (2008). Emerging antiangiogenic treatments for gliomas-efficacy and safety issues. Curr Opin Neurol 21, 736-744.
5. Oronsky BT, Knox SJ, and Scicinski JJ (2012). Is nitric oxide (NO) the last word in radiosensitization? A review. Transl Oncol 5, 66-71.
6. Miller KD, Sweeney CJ, and Sledge GW Jr (2005). Can tumor angiogenesis be inhibited without resistance? EXS 94, 95-112.
7. Thompson EM, Frenkel EP, and Neuwelt EA (2011). The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 76, 87-93.
8. Grabner G, Nöbauer I, Elandt K, Kronnerwetter C, Woehrer A, Marosi C, Prayer D, Trattnig S, and Preusser M (2012). Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T. Magn Reson Imaging 30, 139-147.
9. Wong ET, Gautam S, Malchow C, Lun M, Pan E, and Brem S (2011). Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw 9, 403-407.
10. Ali MM, Janic B, Babajani-Feremi A, Varma NR, Iskander AS, Anagli J, and Arbab AS (2010). Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma. PLoS One 5, e8727.
11. Faivre S, Demetri G, Sargent W, and Raymond E (2007). Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6, 734-745.
12. Petit I, Jin D, and Rafii S (2007). The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 28, 299-307.
13. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, and Brown JM (2010). Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120, 694-705.
14. 31P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts. Magn Reson Med. DOI: 10. 1002/mrm. 24869 [Epub ahead of print 22 July].
15. Taylor JS, Tofts PS, Port R, Evelhoch JL, Knopp M, Reddick WE, Runge VM, and Mayr N (1999). MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging 10, 903-907.
16. Knopp MV, Weiss E, Sinn HP, Mattern J, Junkermann H, Radeleff J, Magener A, Brix G, Delorme S, Zuna I, et al. (1999). Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 10, 260-266.
17. Bagher-Ebadian H, Jain R, Nejad-Davarani SP, Mikkelsen T, Lu M, Jiang Q, Scarpace L, Arbab AS, Narang J, Soltanian-Zadeh H, et al. (2012). Model selection for DCE-T1 studies in glioblastoma. Magn Reson Med 68, 241-251.
18. Ewing JR, Brown SL, Lu M, Panda S, Ding G, Knight RA, Cao Y, Jiang Q, Nagaraja TN, Churchman JL, et al. (2006). Model selection in magnetic resonance imaging measurements of vascular permeability: Gadomer in a 9L model of rat cerebral tumor. J Cereb Blood Flow Metab 26, 310-320.
19. Janic B and Arbab AS (2012). Cord blood endothelial progenitor cells as therapeutic and imaging probes. Imaging Med 4, 477-490.
20. Kumar S, Arbab AS, Jain R, Kim J, Decarvalho AC, Shankar A, Mikkelsen T, and Brown SL (2012). Development of a novel animal model to differentiate radiation necrosis from tumor recurrence. J Neurooncol 108, 411-420.
21. lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res 9, 834-844.
22. Gutova M, Najbauer J, Gevorgyan A, Metz MZ, Weng Y, Shih CC, and Aboody KS (2007). Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS One 2, e243.
23. Yoshida T, Matsuda Y, Naito Z, and Ishiwata T (2012). CD44 in human glioma correlates with histopathological grade and cell migration. Pathol Int 62, 463-470.
24. Arbab AS, Thiffault C, Navia B, Victor SJ, Hong K, Zhang L, Jiang Q, Varma NR, Iskander A, and Chopp M (2012). Tracking of In-111-labeled human umbilical tissue-derived cells (hUTC) in a rat model of cerebral ischemia using SPECT imaging. BMC Med Imaging 12, 33.
25. Zhang L, Li Y, Zhang C, Chopp M, Gosiewska A, and Hong K (2011). Delayed administration of human umbilical tissue-derived cells improved neurological functional recovery in a rodent model of focal ischemia. Stroke 42, 1437-1444.
26. Christensen K, Aaberg-Jessen C, Andersen C, Goplen D, Bjerkvig R, and Kristensen BW (2010). Immunohistochemical expression of stem cell, endothelial cell, and chemosensitivity markers in primary glioma spheroids cultured in serumcontaining and serum-free medium. Neurosurgery 66, 933-947.
27. Weidner N, Semple JP, Welch WR, and Folkman J (1991). Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324, 1-8.
28. Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Prabhu S, Loghin M, Gilbert MR, and Jackson EF (2011). Randomized double-blind placebocontrolled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79, 1487-1495.
29. 14C-sucrose in areas of bloodbrain opening. Magn Reson Med 50, 283-292.
30. Donzella GA, Schols D, Lin SW, Esté JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, et al. (1998). AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4, 72-77.
31. Rempel SA, Dudas S, Ge S, and Gutiérrez JA (2000). Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res 6, 102-111.
32. Oh JW, Drabik K, Kutsch O, Choi C, Tousson A, and Benveniste EN (2001). CXC chemokine receptor 4 expression and function in human astroglioma cells. J Immunol 166, 2695-2704.
33. Ehtesham M, Winston JA, Kabos P, and Thompson RC (2006). CXCR4 expression mediates glioma cell invasiveness. Oncogene 25, 2801-2806.
34. Hong X, Jiang F, Kalkanis SN, Zhang ZG, Zhang XP, DeCarvalho AC, Katakowski M, Bobbitt K, Mikkelsen T, and Chopp M (2006). SDF-1 and CXCR4 are up-regulated by VEGF and contribute to glioma cell invasion. Cancer Lett 236, 39-45.
35. Woerner BM, Warrington NM, Kung AL, Perry A, and Rubin JB (2005). Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. Cancer Res 65, 11392-11399.
36. Zhou Y, Larsen PH, Hao C, and Yong VW (2002). CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem 277, 49481-49487.
37. Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O, Yee H, Voura EB, and Newcomb EW (2006). Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 86, 1221-1232.
38. Yang SX, Chen JH, Jiang XF, Wang QL, Chen ZQ, Zhao W, Feng YH, Xin R, Shi JQ, and Bian XW (2005). Activation of chemokine receptor CXCR4 in malignant glioma cells promotes the production of vascular endothelial growth factor. Biochem Biophys Res Commun 335, 523-528.
39. Munaut C, Nöel A, Hougrand O, Foidart JM, Boniver J, and Deprez M (2003). Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer 106, 848-855.
40. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, and Ratcliffe PJ (1997). Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94, 8104-8109.
41. Taylor J and Gerstner ER (2013). Anti-angiogenic therapy in high-grade glioma (treatment and toxicity). Curr Treat Options Neurol 15, 328-337.
42. Neyns B, Sadones J, Chaskis C, Dujardin M, Everaert H, Lv S, Duerinck J, Tynninen O, Nupponen N, Michotte A, et al. (2011). Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol 103, 491-501.
43. Reardon DA, Vredenburgh JJ, Coan A, Desjardins A, Peters KB, Gururangan S, Sathornsumetee S, Rich JN, Herndon JE, and Friedman HS (2011). Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol 105, 621-627.
44. Pan E, Yu D, Yue B, Potthast L, Chowdhary S, Smith P, and Chamberlain M (2012). A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J Neurooncol 110, 111-118.
45. Brandes AA, Stupp R, Hau P, Lacombe D, Gorlia T, Tosoni A, Mirimanoff RO, Kros JM, and van den Bent MJ (2010). EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer 46, 348-354.
46. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster AD, and Segal RA (2003). A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 100, 13513-13518.
47. Welti JC, Powles T, Foo S, Gourlaouen M, Preece N, Foster J, Frentzas S, Bird D, Sharpe K, van Weverwijk A, et al. (2012). Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis 15, 623-641.